Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
ADC Therapeutics Yönetim
Yönetim kriter kontrolleri 3/4
ADC Therapeutics' CEO is Ameet Mallik, appointed in May 2022, has a tenure of 2.42 years. total yearly compensation is $3.78M, comprised of 19.1% salary and 80.9% bonuses, including company stock and options. directly owns 1.03% of the company’s shares, worth $3.12M. The average tenure of the management team and the board of directors is 2.2 years and 3.9 years respectively.
Anahtar bilgiler
Ameet Mallik
İcra Kurulu Başkanı
US$3.8m
Toplam tazminat
| CEO maaş yüzdesi | 19.1% |
| CEO görev süresi | 2.4yrs |
| CEO sahipliği | 1.0% |
| Yönetim ortalama görev süresi | 2.2yrs |
| Yönetim Kurulu ortalama görev süresi | 3.9yrs |
Son yönetim güncellemeleri
Recent updates
ADC Therapeutics SA (NYSE:ADCT) Surges 34% Yet Its Low P/S Is No Reason For Excitement
Jul 18
Limiting Concerns On ADC Therapeutics' Prospects
Jun 06ADC Therapeutics SA's (NYSE:ADCT) 26% Dip In Price Shows Sentiment Is Matching Revenues
May 30Analysts Are Updating Their ADC Therapeutics SA (NYSE:ADCT) Estimates After Its First-Quarter Results
May 10ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade)
Mar 19ADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching Revenues
Mar 17ADC Therapeutics SA (NYSE:ADCT) Shares Fly 38% But Investors Aren't Buying For Growth
Jan 18ADC Therapeutics: Rising From The Ashes Of A Halted Drug Trial
Dec 29An Intrinsic Calculation For ADC Therapeutics SA (NYSE:ADCT) Suggests It's 38% Undervalued
Dec 14ADC Therapeutics: Navigating A Swirling Drain
Dec 01ADC Therapeutics: Slowly Moving Toward Solvency
Aug 29Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 32%?
Jul 11ADC Therapeutics: Maybe A 2024 Story
May 29Analysts Have Just Cut Their ADC Therapeutics SA (NYSE:ADCT) Revenue Estimates By 28%
May 11ADC Therapeutics SA's (NYSE:ADCT) Shares Lagging The Industry But So Is The Business
Apr 18ADC Therapeutics stock slips after pricing stock offering by seller
Feb 02Does ADC Therapeutics (NYSE:ADCT) Have A Healthy Balance Sheet?
Jan 16Jose Carmona joins ADC Therapeutics as CFO
Dec 19ADC Therapeutics Non-GAAP EPS of $0.13, revenue of $76.32M
Nov 08ADC, Sobi Zynlonta for blood cancer subtype gets EMA panel backing for EU approval
Sep 16ADC Therapeutics gets downgraded at Morgan Stanley, price target cut to $11
Sep 09ADC Therapeutics Non-GAAP EPS of -$0.73, revenue of $17.29M misses by $13.93M
Aug 09CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$215m |
| Mar 31 2024 | n/a | n/a | -US$227m |
| Dec 31 2023 | US$4m | US$721k | -US$240m |
| Sep 30 2023 | n/a | n/a | -US$182m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$200m |
| Dec 31 2022 | US$11m | US$475k | -US$157m |
Tazminat ve Piyasa: Ameet's total compensation ($USD3.78M) is above average for companies of similar size in the US market ($USD2.40M).
Tazminat ve Kazançlar: Ameet's compensation has been consistent with company performance over the past year.
CEO
Ameet Mallik (51 yo)
2.4yrs
Görev süresi
US$3,779,425
Tazminat
Dr. Ameet Mallik M.B.A., M.S, is Director at ADC Therapeutics SA from June 30, 2022. He has been a Director of Atara Biotherapeutics, Inc. since August 2021. Dr. Mallik serves as Chief Executive Officer at...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 2.4yrs | US$3.78m | 1.03% $ 3.1m | |
| Chief Financial Officer | 1.8yrs | US$1.26m | 0.22% $ 664.1k | |
| Chief Medical Officer | 1.8yrs | US$4.40m | 0.24% $ 735.0k | |
| Corporate Controller & Chief Accounting Officer | no data | Veri yok | Veri yok | |
| Chief Technical Operations Officer | 2.8yrs | Veri yok | Veri yok | |
| Chief Scientific Officer | 2.8yrs | Veri yok | Veri yok | |
| Investor Relations Officer | no data | Veri yok | Veri yok | |
| Secretary & Chief Legal Officer | 1.9yrs | Veri yok | Veri yok | |
| Vice President of Investor Relations & Corporate Communications | no data | Veri yok | Veri yok | |
| Senior VP & Chief People Officer | 4.2yrs | Veri yok | Veri yok | |
| Chief Commercial Officer | 1.9yrs | Veri yok | Veri yok |
2.2yrs
Ortalama Görev Süresi
56yo
Ortalama Yaş
Deneyimli Yönetim: ADCT's management team is considered experienced (2.2 years average tenure).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 2.3yrs | US$3.78m | 1.03% $ 3.1m | |
| Board Observer | 1.3yrs | US$846.56k | Veri yok | |
| Vice-Chairman & Lead Independent Director | 5.3yrs | US$212.61k | 0.15% $ 449.3k | |
| Chairman of the Board | 4.5yrs | US$526.73k | 1.6% $ 4.9m | |
| Independent Non-Executive Director | 2.3yrs | US$197.81k | 0.059% $ 179.2k | |
| Independent Non-Executive Director | 6.3yrs | Veri yok | Veri yok | |
| Independent Non-Executive Director | 4.5yrs | US$227.72k | 0.074% $ 226.8k | |
| Independent Director | 1.3yrs | US$127.67k | 0.024% $ 73.5k | |
| Independent Non-Executive Director | 3.3yrs | US$231.33k | 0.098% $ 298.6k | |
| Non-Independent Director | 8yrs | US$194.30k | 0.18% $ 547.8k |
3.9yrs
Ortalama Görev Süresi
57.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: ADCT's board of directors are considered experienced (3.9 years average tenure).